Plain-English translation of NCT07387094 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called XW003 to see if it can help treat obstructive sleep apnea (a condition where breathing stops and starts during sleep) in people who are overweight or obese. Participants will receive either the medication or a placebo (a dummy injection with no active medicine) once a week for up to 48 weeks. The study wants to learn whether this treatment can safely and effectively reduce sleep apnea symptoms and help with weight management.
Many people with sleep apnea struggle with standard treatments like breathing machines, and obesity makes the condition worse. This medication is being tested to see if it offers a new treatment option that could address both the sleep apnea and weight issues at the same time.
You likely qualify if…
You likely don't qualify if…
You would come to the clinic once a week to receive an injection under your skin — either the active medication or placebo — for up to 48 weeks. The study includes a dose-escalation period where the amount of medicine gradually increases. You'll have screening tests at the start (including a sleep study if needed) and follow-up visits to check how the treatment is working and monitor for any side effects.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Hangzhou Sciwind Biosciences Co., Ltd.
Enrollment target
~140 participants
Started
February 2026
Primary completion
December 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.